skip to Main Content

Neoadjuvant Tx Tops Surgery for Pancreatic Cancer

Neoadjuvant Tx Tops Surgery for Pancreatic Cancer
Neoadjuvant chemotherapy followed by surgery led to significantly better survival in newly diagnosed, early-stage pancreatic cancer compared with upfront surgery with or without adjuvant chemotherapy, an analysis of similar patients showed.

Patients had a median overall survival of 26 months with neoadjuvant chemotherapy versus 21 months with upfront surgical resection. The survival advantage for neoadjuvant therapy persisted in a subgroup analysis of patients who received surgery plus adjuvant chemotherapy.

Patients who had upfront surgery had higher-stage tumors, a higher rate of positive lymph nodes, and a higher rate of positive surgical margins, Patricio M. Polanco, MD, of the University of Texas Southwestern Medical Center in Dallas, and co-authors reported online in the Journal of Clinical Oncology. Read more . . .


Back To Top